Characteristics of the pretreatment tumor microenvironment may influence clinical response in patients with refractory large B cell lymphoma treated with axicabtagene ciloleucel (axi-cel) in the pivotal ZUMA-1 Rossi, J. M., Galon, J., Turcan, S., Danan, C., Locke, F. L., Neelapu, S. S., Miklos, D. B., Jacobson, C. A., Lekakis, L. J., Lin, Y., Ghobadi, A., Go, W. Y., Bot, A. AMER ASSOC CANCER RESEARCH. 2018

View details for DOI 10.1158/1538-7445.AM2018-LB-016

View details for Web of Science ID 000468818900188